Overview

Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients

Status:
Completed

Trial end date:
2017-01-05

Target enrollment:

Participant gender:

Summary

This trial evaluated the efficacy of an everolimus-based quadruple low immunosuppressive regimen versus a standard immunosuppressive regimen concerning kidney function in lung transplant recipients.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Collaborator:

Crolll Gmbh

Treatments:

Everolimus
Immunosuppressive Agents
Sirolimus